Analyst Justin Zelin from BTIG reiterated a Buy rating on TScan Therapeutics (TCRX – Research Report) and keeping the price target at $12.00.
Justin Zelin has given his Buy rating due to a combination of factors that highlight the potential of TScan Therapeutics’ programs. The TSC100/101 program showed promising results in reducing relapse rates in patients with AML, ALL, or MDS, as evidenced by the data presented at ASH ’24. The treatment arm demonstrated a significantly lower relapse rate compared to the control, with favorable event-free survival metrics. This suggests a strong clinical differentiation and potential long-term efficacy, which is expected to be further clarified with upcoming 2-year relapse data.
Additionally, the TSC200+ program presents an underappreciated opportunity, with its multi-antigen targeting approach in solid tumors. The initial data expected in 2H25 could reveal meaningful responses and durability, which would further support the stock’s potential. Financially, TScan Therapeutics maintains a solid cash position, providing a runway for continued development. These factors, combined with a strategic focus on advancing TSC-101 and the anticipated pivotal study, underpin Zelin’s optimistic outlook and reaffirmation of the Buy rating.
Zelin covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics, IDEAYA Biosciences, and Verastem. According to TipRanks, Zelin has an average return of 2.0% and a 30.71% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.